Domestic drug companies in India are preparing to launch affordable generics of the diabetes drug Empagliflozin after the ...

With the expiration of Boehringer Ingelheim’s patent on Empagliflozin, several Indian pharmaceutical companies are set to ...

Indian Pharmaceuticals Market has delivered marginally lower revenue at 7.5% year on year in February 2025, compared to 8.7% ...

There are several domestic drug companies that seem to be all prepared to transform diabetes therapy with the launch of the ...

The biggest advantage of the drug going off patent is that the prices will plummet. The patented medicine, sold as Jardiance, ...

While Metformin continues to be the standard first-line treatment for Type-2 diabetes, newer therapies such as SGLT2 ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, ...

Indian drug companies are set to revolutionize diabetes treatment with affordable generic versions of Empagliflozin, ...

Mankind Pharma has stated its intent to pursue appropriate legal action, including filing an appeal if necessary.

Pharmaceutical firm Mankind Pharma Ltd on Friday (February 28) said it has received a ₹111.68 crore tax demand from the ...

Currently priced at Rs 60 per tablet, Empagliflozin’s generic versions will be available for as low as Rs 9-Rs 14 per tablet, significantly reducing costs for millions of patients, states the report.